Ideas

December 19, 2017

Published by admin_auro at December 19, 2017

Categories

Cardiac rejuvenation therapy: A therapeutic mix encompassing Pyridoxamine (PM) and Sulforaphane (SFN) suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy via up regulation of its target gene, 19/December/2017, 10.54 pm

What we say: Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Cardiac rejuvenation therapy: Cardiac rejuvenation therapy: A therapeutic mix encompassing Pyridoxamine (PM) and Sulforaphane (SFN) suppresses […]

December 19, 2017

Published by admin_auro at December 19, 2017

Categories

Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: A pharmaceutical mixture [PMSFN] encompassing Pyridoxamine (PM) and Sulforaphane (SFN) increases the expression of ERBB2/Her2 and promotes dedifferentiation of cardiomyocytes via down regulation of its target gene, 19/December/2017, 10.31 pm,

Introduction: What they say A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was […]

December 19, 2017

Published by admin_auro at December 19, 2017

Categories

Molecular therapy for heart regeneration and repair: A therapeutic mix encompassing Pyridoxamine (PM) and Sulforaphane (SFN) increases Agrin expression, activates Yap and ERK-mediated signaling, replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up regulation of its target gene, 19/December/2017, 10.17 pm

Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, […]

December 19, 2017

Published by admin_auro at December 19, 2017

Categories

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Macbecin, Temozolomide, EGCG, Salinomycin, Fluvastatin, Forodesine and Chloroquine (MTESFFC) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 19/December/2017, 10.02 pm

Introduction:What they say: A recent study from Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA; Jonsson Comprehensive Cancer […]